BI Asset Management Fondsmaeglerselskab A S Has $3.29 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

BI Asset Management Fondsmaeglerselskab A S increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 39.0% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 4,619 shares of the biopharmaceutical company's stock after acquiring an additional 1,297 shares during the period. BI Asset Management Fondsmaeglerselskab A S's holdings in Regeneron Pharmaceuticals were worth $3,290,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Pamalican Asset Management Ltd bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth about $4,915,000. Intact Investment Management Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth approximately $356,000. Rhenman & Partners Asset Management AB boosted its position in shares of Regeneron Pharmaceuticals by 11.4% in the fourth quarter. Rhenman & Partners Asset Management AB now owns 43,457 shares of the biopharmaceutical company's stock valued at $30,956,000 after acquiring an additional 4,457 shares during the period. Principal Financial Group Inc. grew its stake in shares of Regeneron Pharmaceuticals by 1.7% in the third quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company's stock worth $181,961,000 after acquiring an additional 2,828 shares during the last quarter. Finally, Fagan Associates Inc. increased its position in Regeneron Pharmaceuticals by 42.2% during the fourth quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company's stock worth $9,205,000 after acquiring an additional 3,832 shares during the period. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock traded up $2.88 during trading hours on Friday, reaching $602.64. 964,377 shares of the company were exchanged, compared to its average volume of 723,778. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $525.99 and a fifty-two week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The stock's fifty day moving average is $637.38 and its two-hundred day moving average is $725.82. The company has a market cap of $65.88 billion, a price-to-earnings ratio of 15.74, a P/E/G ratio of 2.34 and a beta of 0.44.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $11.21 by $0.86. The firm had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $11.86 EPS. Sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were given a $0.88 dividend. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.58%. Regeneron Pharmaceuticals's payout ratio is 2.30%.

Wall Street Analyst Weigh In

Several research firms have issued reports on REGN. Robert W. Baird decreased their price target on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating on the stock in a research report on Friday. Sanford C. Bernstein lowered their price target on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating on the stock in a research note on Tuesday, January 7th. Leerink Partners upgraded Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and raised their price objective for the stock from $762.00 to $834.00 in a research report on Wednesday, February 5th. Leerink Partnrs upgraded Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, February 5th. Finally, BMO Capital Markets reduced their target price on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an "overweight" rating for the company in a research report on Tuesday, February 4th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, nineteen have issued a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $945.32.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.